The Westaim Corporation (TSXV:WED)

Longboard Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-46.88	-16.18	183.98	17.96	28.21	-34.4
Depreciation & Amortization	0.09	0.12	0.14	0.14	0.15	0.15
Asset Writedown & Restructuring Costs	-	-	-	-	-4.19	0.68
Loss (Gain) From Sale of Investments	8.23	-25.42	-199.72	-15.97	-21.36	50.78
Loss (Gain) on Equity Investments	5.28	3.91	-4.44	-0.78	-10	0.1
Stock-Based Compensation	6.51	5.7	5.52	0.87	0.39	0.35
Other Operating Activities	-14.2	-7.99	1.32	-3.6	-0.16	0.47
Change in Accounts Payable	3.07	-5.39	10.68	-1.15	1.11	0.11
Change in Other Net Operating Assets	-1.32	-1.32	-0.57	0.06	0.74	0.3
Operating Cash Flow	-39.22	-46.57	-3.09	-2.46	-5.12	18.54
Operating Cash Flow Growth	-	-	-	-	-	1278.59%
Capital Expenditures	-0.01	-0.01	-	-	-0.01	-0.03
Investment in Securities	-57.64	-20.21	6.68	1.9	-	-24.01
Other Investing Activities	-31.6	-13	-	-	4	-8
Investing Cash Flow	-89.25	-33.21	6.68	1.9	3.99	-32.04
Issuance of Common Stock	256.39	256.39	192.32	-	-	-
Repurchase of Common Stock	-2.72	-9.73	-26.39	-2.56	-1.06	-
Financing Cash Flow	253.67	246.65	128.02	-2.56	-1.06	-
Net Cash Flow	125.2	166.88	131.6	-3.12	-2.18	-13.5
Free Cash Flow	-39.23	-46.57	-3.09	-2.46	-5.13	18.51
Free Cash Flow Growth	-	-	-	-	-	1279.14%
Free Cash Flow Margin	-782.66%	-120.81%	-1.45%	-8.97%	-15.21%	-
Free Cash Flow Per Share	-1.83	-2.17	-0.13	-0.10	-0.21	0.78
Cash Interest Paid	-	-	1.48	1.93	1.98	1.86
Levered Free Cash Flow	-43.41	-27.25	140.55	11.55	19.25	-19.61
Unlevered Free Cash Flow	-43.41	-27.25	141.18	12.73	20.5	-18.44
Change in Working Capital	1.75	-6.72	10.11	-1.08	1.85	0.4

Source: S&P Global Market Intelligence. Standard template. Financial Sources.